Skip to main content

Advertisement

Table 1 Patient characteristics according to dosage reduction and in total

From: Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects

  Dosage reduction  
Yes (<=80% dosage) No (=100% dosage) Total T-test Chi2
N (%) N (%) N (%) p value
Age Mean/Median 56.5 59.0 58.4 58.0 57.6 59.0 .440
  < 65 32 69.6% 42 66.7% 74 67.9% .749
> = 65 14 30.4% 21 33.3% 35 32.1%  
Sex Male 29 63.0% 46 73.0% 75 68.8% .267
Female 17 37.0% 17 27.0% 34 31.2%  
T stage T3 17 37.0% 23 36.5% 40 36.7%  
T4 22 47.8% 22 34.9% 44 40.4% .205
Tx 7 15.2% 18 28.6% 25 22.9%  
N stage N0 4 8.7% 5 7.9% 9 8.3%  
N1 14 30.4% 16 25.4% 30 27.5% .796
N2 18 39.1% 23 36.5% 41 37.6%  
Nx 10 21.7% 19 30.2% 29 26.6%  
Grading G2 27 58.7% 40 63.5% 67 61.5%  
G3 18 39.1% 19 30.2% 37 33.9% .419
Gx 1 2.2% 4 6.3% 5 4.6%  
L stage L0 6 13.0% 7 11.1% 13 11.9%  
L1 23 50.0% 15 23.8% 38 34.9% .010
Lx 17 37.0% 41 65.1% 58 53.2%  
V stage V0 13 28.3% 11 17.5% 24 22.0%  
V1 14 30.4% 10 15.9% 24 22.0% .030
Vx 19 41.3% 42 66.7% 61 56.0%  
Charlson Comorbidity Score 6 32 69.6% 44 69.8% 76 69.7%  
7 7 15.2% 13 20.6% 20 18.3%  
8 6 13.0% 4 6.3% 10 9.2% .336
9 0 0.0% 2 3.2% 2 1.8%  
10 1 2.2% 0 0.0% 1 0.9%  
Oncological resection/Surgery Yes 35 76.1% 37 58.7% 72 66.1% .059
No 11 23.9% 26 41.3% 37 33.9%  
No. of CTX lines 1 11 23.9% 17 27.0% 28 25.7%  
2 23 50.0% 34 54.0% 57 52.3%  
3 11 23.9% 11 17.5% 22 20.2% .587
4 0 0.0% 1 1.6% 1 0.9%  
5 1 2.2% 0 0.0% 1 0.9%  
Biological Yes 21 45.7% 26 41.3% 47 43.1% .648
No 25 54.3% 37 58.7% 62 56.9%  
CTX regimen sequence FOLFOX- > FOLFIRI 30 65.2% 27 42.9% 57 52.3%  
FOLFIRI- > FOLFOX 3 6.5% 13 20.6% 16 14.7% .044
FOLFOX 10 21.7% 13 20.6% 23 21.1%  
FOLFIRI 3 6.5% 10 15.9% 13 11.9%  
Total 46 100.0% 63 100.0% 109 100.0%